Dr. Benjamin A. Jones, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Alabama College of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 140
Licensed in Alabama since 2015, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of South Alabama College of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AL license 33841 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
- Grandview Medical Center Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 140
- Services billed
- 378
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 109 | 80 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 30 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 19 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Birmingham, AL | 178 |
| Baclofen Other prescribers in Birmingham, AL | 101 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Birmingham, AL | 74 |
| Levetiracetam Other prescribers in Birmingham, AL | 64 |
| Dalfampridine Er (dalfampridine) | 59 |
| Clonazepam Other prescribers in Birmingham, AL | 51 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Birmingham, AL | 47 |
| Kesimpta Pen (ofatumumab) | 46 |
| Sumatriptan Succinate Other prescribers in Birmingham, AL | 41 |
| Carbamazepine Er (carbamazepine) Other prescribers in Birmingham, AL | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $398 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $175 |
|---|---|
| Biogen, Inc. | $150 |
| Kite Pharma, Inc. | $29.55 |
| Csl Behring | $22.83 |
| GlaxoSmithKline, LLC. | $20.88 |
| Consulting Fee | $325 |
|---|---|
| Food and Beverage | $73.26 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
| Biogen, Inc. May 21, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $48,256 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. · Terminated · NCT03906071
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.